The DOI matches its Crossref record.
Intravenous cyclophosphamide therapy for progressive interstitial pneumonia in patients with polymyositis/dermatomyositis
Abstract
OBJECTIVES: To study the efficacy and safety of monthly intravenous pulse cyclophosphamide (IVCYC) therapy for progressive interstitial pneumonia in polymyositis/dermatomyositis (PM/DM). METHODS: Seventeen patients with PM/DM/amyopathic DM (mean age 51.4 +/- 10.4, mean follow-up 32 months) who received IVCYC for progressive interstitial pneumonia between August 1993 and October 2002 were studied. Nine patients had failed to respond to previous treatment with high-dose steroid and/or immunosuppressant. Cyclophosphamide (300-800 mg/m2) was given at least six times every 4 weeks. Oral prednisolone (0.5-1 mg/kg/day) was administered for the first 2 weeks and was gradually tapered. Response to treatment was evaluated based on the degree of exertional dyspnea, pulmonary function test and high-resolution computed tomography (HRCT). RESULTS: Eleven of 17 patients showed improvement in their dyspnea; six out of seven patients who had required oxygen treatment before IVCYC no longer did so after IVCYC. Eight of 17 patients had >or=10% improvement of vital capacity (VC)% and 9/17 had >or=10 point reduction in their HRCT score. Twelve patients had exhibited at least one result. Two patients with anti-Jo-1 antibodies showed a flare-up of interstitial pneumonia or myositis. After the IVCYC therapy, mean VC% improved by 15% (from 68 to 83%, P = 0.0034). The extent of abnormal lesions in HRCT was reduced from 24 to 13% (P = 0.0055). There was neither death nor severe toxicities observed. CONCLUSIONS: In this open-label study, IVCYC improved symptoms, pulmonary function tests and HRCT findings in patients with PM/DM. Longitudinal controlled studies are required to further confirm the efficacy of IVCYC.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Idiopathic inflammatory myopathies
Lundberg, I. E., Fujimoto, M., Vencovsky, J., Aggarwal, R., Holmqvist, M., Christopher-Stine, L., Mammen, A. L., & Miller, F. W. (2021) · Nature Reviews Disease Primers · doi:10.1038/s41572-021-00321-x · Cited by 703
Interstitial Lung Disease Associated With the Idiopathic Inflammatory Myopathies
Connors, G. R., Christopher-Stine, L., Oddis, C. V., & Danoff, S. K. (2010) · Chest · doi:10.1378/chest.10-0180 · Cited by 564
George, P. M., Spagnolo, P., Kreuter, M., Altinisik, G., Bonifazi, M., Martinez, F. J., Molyneaux, P. L., Renzoni, E. A., Richeldi, L., Tomassetti, S., et al. (2020) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(20)30355-6 · Cited by 349
Hamaguchi, Y., Kuwana, M., Hoshino, K., Hasegawa, M., Kaji, K., Matsushita, T., Komura, K., Nakamura, M., Kodera, M., Suga, N., et al. (2011) · Archives of Dermatology · doi:10.1001/archdermatol.2011.52 · Cited by 333
Self-citationGono, T., Kawaguchi, Y., Satoh, T., Kuwana, M., Katsumata, Y., Takagi, K., Masuda, I., Tochimoto, A., Baba, S., Okamoto, Y., et al. (2010) · Rheumatology · doi:10.1093/rheumatology/keq149 · Cited by 319
Metadata
- Authors
- Yamasaki, Y., Yamada, H., Yamasaki, M., Ohkubo, M., Azuma, K., Matsuoka, S., Kurihara, Y., Osada, H., Satoh, M., & Ozaki, S.
- Venue
- Rheumatology
- Publisher
- Oxford University Press (OUP)
- Published
- 2007-01-01
- Volume
- 46
- Issue
- 1
- Pages
- 124-130
- ISSN
- 1462-0324 (ISSN-L)
- 1462-0332
- OpenAlex
- W2126996887
- Cited by
- 208
- References
- 0
- FWCI
- 2.88
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Intravenous cyclophosphamide therapy for progressive interstitial pneumonia in patients with polymyositis/dermatomyositis. https://app.cochat.ai/papers/10.1093/rheumatology/kel112
- The paper
- Yamasaki, Y., Yamada, H., Yamasaki, M., Ohkubo, M., Azuma, K., Matsuoka, S., Kurihara, Y., Osada, H., Satoh, M., & Ozaki, S. (2007). Intravenous cyclophosphamide therapy for progressive interstitial pneumonia in patients with polymyositis/dermatomyositis. Rheumatology. https://doi.org/10.1093/rheumatology/kel112
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.